C. STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Jun. 30, 2019

Equity [Abstract]

Changes in stockholders' equity

The changes in stockholders’ equity during the nine months ended June 30, 2019 are as follows:

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total
BALANCES AT OCTOBER 1, 2018		28,034,487		$	280,346		$	331,312,184		$	(331,591,614	)	$	916
Warrant exercises		298,682			2,987			646,766			-			649,753
401(k) contributions paid in common stock		12,279			123			35,118			-			35,241
Stock issued to nonemployees for services		62,784			628			201,752			-			202,380
Shares returned for settlement of clinical research costs		(564,905	)		(5,649	)		5,649			-			-
Equity based compensation - employees		-			-			573,660			-			573,660
Net income		-			-			-			1,245,902			1,245,902
BALANCES AT DECEMBER 31, 2018		27,843,327			278,435			332,775,129			(330,345,712	)		2,707,852
Warrant exercises		1,523,933			15,239			2,640,395			-			2,655,634
401(k) contributions paid in common stock		10,419			104			36,779			-			36,883
Stock issued to nonemployees for services		77,449			774			224,855			-			225,629
Equity based compensation - employees		(3,500	)		(35	)		530,865			-			530,830
Shares issued for settlement of clinical research costs		500,000			5,000			1,285,000			-			1,290,000
Stock issuance costs		-			-			(43,625	)		-			(43,625	)
Net loss		-			-			-			(6,447,681	)		(6,447,681	)
BALANCES AT MARCH 31, 2019		29,951,628			299,517			337,449,398			(336,793,393	)		955,522
Warrant exercises		4,014,109			40,141			10,212,680			-			10,252,821
401(k) contributions paid in common stock		4,339			43			36,318			-			36,361
Stock issued to nonemployees for services		20,825			208			140,062			-			140,270
Equity based compensation - employees		(4,000	)		(40	)		1,521,861			-			1,521,821
Option exercises		42,770			428			96,862			-			97,290
Purchase of stock by officers and directors		37,243			372			234,625			-			234,997
Stock issuance costs		-			-			(8,010	)		-			(8,010	)
Net loss		-			-			-			(12,084,768	)		(12,084,768	)
BALANCES AT JUNE 30, 2019		34,066,914		$	340,669		$	349,683,796		$	(348,878,161	)	$	1,146,304

The changes in stockholders’ deficit during the nine months ended June 30, 2018 are as follows:

					Additional
	Common		Stock		Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total
BALANCES AT OCTOBER 1, 2017		11,903,133	$	119,031	$	296,298,401		$	(299,754,409	)	$	(3,336,977	)
Sale of common stock		1,289,478		12,895		2,437,105			-			2,450,000
401(k) contributions paid in common stock		18,984		190		35,690			-			35,880
Stock issued to nonemployees for services		13,705		137		25,270			-			25,407
Equity based compensation - employees		-		-		1,448,098			-			1,448,098
Warrants issued with notes payable		-		-		656,382			-			656,382
Conversion of notes payable to common stock		32,751		328		74,672			-			75,000
Net loss		-		-		-			(6,187,830	)		(6,187,830	)
BALANCES AT DECEMBER 31, 2017		13,258,051		132,581		300,975,618			(305,942,239	)		(4,834,040	)
Sale of common stock		2,501,145		25,011		4,652,130			-			4,677,141
401(k) contributions paid in common stock		25,901		259		36,261			-			36,520
Stock issued to nonemployees for services		124,082		1,241		227,254			-			228,495
Equity based compensation - employees		-		-		279,817			-			279,817
Conversion of notes payable to common stock		55,373		554		108,746			-			109,300
Shares issued for settlement of clinical research costs		660,000		6,600		1,240,800			-			1,247,400
Stock issuance cost		-		-		(94,773	)		-			(94,773	)
Net loss		-		-		-			(4,708,135	)		(4,708,135	)
BALANCES AT MARCH 31, 2018		16,624,552		166,246		307,425,853			(310,650,374	)		(3,058,275	)
Warrant exercises		1,117,644		11,177		2,906,619			-			2,917,796
401(k) contributions paid in common stock		39,862		399		36,274			-			36,673
Stock issued to nonemployees for services		81,604		816		208,387			-			209,203
Equity based compensation - employees		-		-		465,487			-			465,487
Conversion of notes payable and interest to common stock		1,106,806		11,068		2,179,648			-			2,190,716
Shares issued for settlement of clinical research costs		600,000		6,000		1,704,000			-			1,710,000
Warrants issued with notes payable		-		-		291,234			-			291,234
Net loss		-		-		-			(6,014,568	)		(6,014,568	)
BALANCES AT JUNE 30, 2018		19,570,468	$	195,706	$	315,217,502		$	(316,664,942	)	$	(1,251,734	)

Stock options, stock bonuses and compensation granted by the Company

Underlying share information for equity compensation plans as of June 30, 2019 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans
Incentive Stock Options Plans		138,400		99,962		N/A		385
Non-Qualified Stock Option Plans		6,387,200		6,193,237		N/A		115,156
Stock Bonus Plans		783,760		N/A		327,267		456,460
Stock Compensation Plan		634,000		N/A		122,221		493,369
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Underlying share information for equity compensation plans as of September 30, 2018 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans
Incentive Stock Option Plans		138,400		123,558		N/A		385
Non-Qualified Stock Option Plans		3,387,200		3,036,569		N/A		309,526
Stock Bonus Plans		783,760		N/A		297,230		486,497
Stock Compensation Plan		134,000		N/A		118,590		15,410
Incentive Stock Bonus Plan		640,000		N/A		624,000		16,000

Stock option activity

	Nine Months Ended June 30,
	2019		2018
Granted		3,268,862		1,858,108
Exercised		42,770		-
Expired		29,322		26,395
Forfeited		63,698		1,393

	Three Months Ended June 30,
	2019		2018
Granted		3,268,362		1,847,808
Exercised		42,770		-
Expired		26,922		2,016
Forfeited		39,505		-

Derivative liabilities, warrants and other options

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	2/18/2020
Series V	5/28/2015		810,127	$	19.75	5/28/2020
Series UU	6/11/2018		163,544	$	2.80	6/11/2020
Series W	10/28/2015		688,930	$	16.75	10/28/2020
Series X	1/13/2016		120,000	$	9.25	1/13/2021
Series Y	2/15/2016		26,000	$	12.00	2/15/2021
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021
Series BB	8/26/2016		16,000	$	13.75	8/22/2021
Series Z	5/23/2016		264,000	$	13.75	11/23/2021
Series FF	12/8/2016		68,048	$	3.91	12/1/2021
Series CC	12/8/2016		611,463	$	5.00	12/8/2021
Series HH	2/23/2017		6,500	$	3.13	2/16/2022
Series AA	8/26/2016		200,000	$	13.75	2/22/2022
Series JJ	3/14/2017		9,450	$	3.13	3/8/2022
Series LL	4/30/2017		26,398	$	3.59	4/30/2022
Series MM	6/22/2017		893,491	$	1.86	6/22/2022
Series NN	7/24/2017		473,798	$	2.52	7/24/2022
Series OO	7/31/2017		60,000	$	2.52	7/31/2022
Series II	3/14/2017		95,000	$	3.00	9/14/2022
Series RR	10/30/2017		495,326	$	1.65	10/30/2022
Series SS	12/19/2017		514,476	$	2.09	12/18/2022
Series TT	2/5/2018		760,758	$	2.24	2/5/2023
Series PP	8/28/2017		112,500	$	2.30	2/28/2023
Series WW	7/2/2018		1,950	$	1.63	6/28/2023
Series VV	7/2/2018		90,000	$	1.75	1/2/2024
Consultants	7/28/17		10,000	$	2.18	7/27/2027

Tabular disclosure of derivative liabilities at fair value

	June 30, 2019		September 30, 2018
Series S warrants	$	-	$	33
Series V warrants		1,249,835		770,436
Series W warrants		2,131,237		999,081
Series Z warrants		1,172,626		487,767
Series ZZ warrants		72,185		34,215
Series AA warrants		963,990		380,474
Series BB warrants		64,256		28,456
Series CC warrants		3,699,989		1,779,724
Series DD warrants		-		1,249,287
Series EE warrants		-		1,249,287
Series FF warrants		433,091		188,921
Series GG warrants		-		607,228
Series HH warrants		44,050		58,816
Series II warrants		660,020		660,135
Series JJ warrants		64,252		88,642
Series KK warrants		-		656,930
Series LL warrants		177,299		77,632
Total warrant liabilities	$	10,732,830	$	9,317,064

Schedule of gains and (losses) on derivative liabilities

The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:

	2019			2018
Series S warrants	$	33		$	(756,261	)
Series V warrants		(479,399	)		22,842
Series W warrants		(1,132,156	)		18,478
Series Z warrants		(684,859	)		34,682
Series ZZ warrants		(37,970	)		2,103
Series AA warrants		(583,516	)		28,337
Series BB warrants		(35,800	)		1,988
Series CC warrants		(2,007,287	)		181,244
Series DD warrants		1,249,287			5,492
Series EE warrants		1,249,287			5,492
Series FF warrants		(244,170	)		23,119
Series GG warrants		195,228			170,131
Series HH warrants		(22,859	)		7,962
Series II warrants		(593,960	)		250,578
Series JJ warrants		(32,954	)		11,970
Series KK warrants		(55,622	)		169,808
Series LL warrants		(99,667	)		10,002
Net (loss) gain on warrant liabilities	$	(3,316,384	)	$	187,967

The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:

	2019			2018
Series S warrants	$	-		$	(768,188	)
Series V warrants		(974,251	)		26,389
Series W warrants		(1,748,184	)		42,609
Series Z warrants		(799,690	)		26,587
Series ZZ warrants		(50,608	)		1,914
Series AA warrants		(676,784	)		19,661
Series BB warrants		(43,536	)		1,695
Series CC warrants		(2,346,985	)		139,325
Series DD warrants		-			36
Series EE warrants		-			36
Series FF warrants		(278,773	)		15,818
Series GG warrants		88,478			132,712
Series HH warrants		(33,501	)		5,279
Series II warrants		(709,303	)		199,970
Series JJ warrants		(48,880	)		7,960
Series KK warrants		(169,089	)		132,884
Series LL warrants		(114,413	)		6,695
Net loss on warrant liabilities	$	(7,905,519	)	$	(8,618	)

Other non-operating gain (loss)

	Nine Months Ended					Three Months Ended
	6/30/2019		6/30/2018			6/30/2019		6/30/2018
Amount realized through the sale of shares	$	3,167,197	$	2,785,932		$	1,455,844	$	1,560,641
Fair value of shares upon issuance		1,290,000		2,957,400			-		1,710,000
Other non-operating gain (loss)	$	1,877,197	$	(171,468	)	$	1,455,844	$	( 149,359	)